Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

CBD for bladder control after spinal cord injury

Official title: Cannabinoid Modulation for Neurogenic Lower Urinary Tract Dysfunction in Spinal Cord Injury

Run by University of Wisconsin, Madison · NCT06840899 · Data updated 2026-11-12

This test gives adults with recent supra‑sacral spinal cord injury purified CBD (Epidiolex) twice daily for 90 days to see if it reduces urinary incontinence and other bladder symptoms.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorUniversity of Wisconsin, Madison
Academic / other
Locations1 site (Madison, Wisconsin)
StatusRecruiting
StartedFebruary 13, 2026
Main results expectedMay 2028
Study endsMay 2028
Registry record updatedSeptember 16, 2026
Trial IDNCT06840899 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 with supra‑sacral spinal cord injury who have neurogenic lower urinary tract dysfunction with ≥2 incontinence episodes per day and can attend in-person visits at the University of Wisconsin–Madison are ideal candidates.

Probably not a fit

Patients with recent intravesical Botox, those on high-dose anticholinergics, ongoing non-study cannabis use, or significant mood/thought disorders were excluded and may not be helped by this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 pilot feasibility trial gives adult participants with supra‑sacral spinal cord injury purified cannabidiol (Epidiolex) 100 mg twice daily for 90 days to target neurogenic lower urinary tract dysfunction after resolution of spinal shock. Eligible participants must have at least two urinary incontinence episodes per day and meet inclusion/exclusion criteria; key exclusions include recent intravesical Botox, high-dose anticholinergic use, active non-study cannabis use, and certain mood/thought disorders. Study measures include changes in incontinence frequency and other urinary symptoms, feasibility outcomes such as recruitment and adherence, and safety/tolerability monitoring. All dosing and follow-up occur at the University of Wisconsin–Madison with urine drug screening and standardized questionnaires.

Why it matters

Potential benefit: If successful, CBD could reduce daily incontinence episodes and improve bladder-related quality of life after spinal cord injury.

How similar studies have gone: Use of purified CBD specifically for neurogenic bladder in humans is largely novel, with limited clinical data and mostly preclinical or anecdotal reports.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* \>18 years of age
* History of supra-sacral spinal cord injury of any mechanism
* Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock)
* Willingness to participate in drug intervention trial
* English-speaking (able to provide consent and complete questionnaires)

Exclusion Criteria:

* History of intravesical Botox
* Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms
* Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported
* Thought or mood disorder aside from depression

Where it's running

  • University of Wisconsin - Madison
    Madison, Wisconsin, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.